Articles related to PRECISION MEDICINE

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

Tempus AI, leveraging one of the world’s largest clinical and molecular oncology data libraries, files for an IPO, aiming to raise substantial funds to support its mission of advancing AI-powered precision medicine.

Manifest Technologies is spearheading the use of AI in developing targeted treatments for CNS disorders, aiming to refine patient selection in clinical trials and enhance therapeutic outcomes.

As physicians, understanding the new biomarker legislation is crucial—it not only shapes insurance coverage but also influences clinical decision-making and patient access to precision medicine, potentially leading to more cost-effective and targeted care.